Brands Headquartered in Basel

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Prescription oncology medicine (everolimus) used to treat certain cancers and tuberous sclerosis complex, developed and marketed by Novartis AG.

Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Genentech and owned by Roche, FDA approved February 26, 2004, that reached peak global sales of $7.1 billion in 2019 and now faces biosimilar competition including Mvasi (Amgen) and multiple other approved alternatives.

Prescription immunosuppressant medication (mycophenolate mofetil) for preventing organ rejection in transplant recipients, originally developed by Syntex Laboratories and now marketed by Roche.

Prescription biologic medication treating psoriasis, psoriatic arthritis, and other autoimmune conditions.

Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia.

Prescription immunosuppressant medication for treating relapsing-remitting multiple sclerosis, manufactured and marketed by Novartis.

Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.

Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1) developed by Genentech using ImmunoGen's DM1 cytotoxic technology, FDA approved February 22, 2013, for HER2-positive metastatic breast cancer and later for early-stage HER2-positive breast cancer following the KATHERINE trial.

Prescription biologic medication for treating age-related macular degeneration and diabetic retinopathy, manufactured and marketed by Novartis.

Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.

Roche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genentech and IDEC Pharmaceuticals, FDA approved November 26, 1997, as the first monoclonal antibody approved for cancer treatment, now facing biosimilar competition from Truxima, Ruxience, and Riabni.

Independent global leader in generic and biosimilar pharmaceuticals, spun off from Novartis in October 2023 and publicly traded on the SIX Swiss Exchange (SDZ), reporting 9M 2025 net sales of USD 8.057 billion with biosimilars accounting for 27% of total sales.

Oseltamivir antiviral medication invented by Gilead Sciences and licensed to Roche in 1996, FDA approved October 27 1999, that became a cornerstone of global influenza pandemic preparedness stockpiles.

Roche's first-generation EGFR tyrosine kinase inhibitor (erlotinib) co-developed by Genentech and OSI Pharmaceuticals, FDA approved November 18, 2004, for EGFR-mutant non-small cell lung cancer and pancreatic cancer, with the branded product now discontinued as generic erlotinib is widely available.

Prescription oncology medication for treating chronic myeloid leukemia, owned by Novartis, facing generic competition after its US patent expired in January 2024, with nilotinib generics now available in the market.

Over-the-counter cold and flu relief medication combining multiple active ingredients for symptom relief, owned by Haleon, a British consumer health company spun off from GSK in 2022.

Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech, FDA approved April 30, 1998, as the first oral chemotherapy for metastatic breast cancer and later for metastatic colorectal cancer, now available as generic capecitabine following patent expiration.